The Power to Create Medicines That Reach Patients—Passing SHIONOGI’s Baton of Innovation to the N...

The Power to Create Medicines That Reach Patients—Passing SHIONOGI’s Baton of Innovation to the Next Generation  Shionogi Inc.

Shionogi & Co. (SGIOF) Price Target Increased by 11.63% to 17.40 - Nasdaq

Shionogi & Co. (SGIOF) Price Target Increased by 11.63% to 17.40  Nasdaq

Shionogi Lifts Profit Outlook on HIV Royalties, Overseas Growth - Bloomberg.com

Shionogi Lifts Profit Outlook on HIV Royalties, Overseas Growth  Bloomberg.com

Yomiuri: Nobel Prize Winner, Shionogi Jointly Developing New Cancer Drug - MarketWatch

Yomiuri: Nobel Prize Winner, Shionogi Jointly Developing New Cancer Drug  MarketWatch

BRIEF—Shionogi launches new form of Xofluza - The Pharma Letter

BRIEF—Shionogi launches new form of Xofluza  The Pharma Letter

Shionogi to Present New Data from Anti-Infective Portfolio at IDWeek - Yahoo Finance

Shionogi to Present New Data from Anti-Infective Portfolio at IDWeek  Yahoo Finance

FDA Accepts Shionogi’s NDA for Ensitrelvir Oral Antiviral in COVID-19 Postexposure Prevention - C...

FDA Accepts Shionogi’s NDA for Ensitrelvir Oral Antiviral in COVID-19 Postexposure Prevention  Contagion Live

The Bull Case For Shionogi (TSE:4507) Could Change Following Cost-Driven Profit Outlook Amid Reve...

The Bull Case For Shionogi (TSE:4507) Could Change Following Cost-Driven Profit Outlook Amid Revenue Slowdown  simplywall.st

FDA Accepts Shionogi’s Ensitrelvir NDA as the First Oral Therapy for the Prevention of COVID-19 F...

FDA Accepts Shionogi’s Ensitrelvir NDA as the First Oral Therapy for the Prevention of COVID-19 Following Exposure  Business Wire

Accelerating drug discovery with AI innovation - SAS: Data and AI Solutions

Accelerating drug discovery with AI innovation  SAS: Data and AI Solutions

Global pharmaceutical company Shionogi joins Paddington Life Sciences Partners - Imperial College...

Global pharmaceutical company Shionogi joins Paddington Life Sciences Partners  Imperial College Healthcare NHS Trust

Shionogi strikes research and option deal with BioVersys for antibacterial assets - FirstWord Pharma

Shionogi strikes research and option deal with BioVersys for antibacterial assets  FirstWord Pharma

BioVersys and Shionogi agree to develop ansamycin leads - Pharmaceutical Technology

BioVersys and Shionogi agree to develop ansamycin leads  Pharmaceutical Technology

Shionogi puts more than $600M on the table for Swiss biotech's antibiotic program - Fierce Biotech

Shionogi puts more than $600M on the table for Swiss biotech's antibiotic program  Fierce Biotech

FDA Accepts Shionogi’s Ensitrelvir NDA for COVID PEP - Infectious Disease Special Edition

FDA Accepts Shionogi’s Ensitrelvir NDA for COVID PEP  Infectious Disease Special Edition

Enrollment Update - Shionogi Inc.

Enrollment Update  Shionogi Inc.

BioVersys and Shionogi Enter Into Global Research Collaboration For Broad-Spectrum Non-Tuberculou...

BioVersys and Shionogi Enter Into Global Research Collaboration For Broad-Spectrum Non-Tuberculous Mycobacteria (NTM) Clinical Candidate  Yahoo Finance

Shionogi (TSE:4507): Unpacking Valuation After Upbeat Forecast, Fetroja® Results, and New Dividen...

Shionogi (TSE:4507): Unpacking Valuation After Upbeat Forecast, Fetroja® Results, and New Dividend  simplywall.st

Shionogi to buy Japan Tobacco's pharma units for over $1B - FirstWord Pharma

Shionogi to buy Japan Tobacco's pharma units for over $1B  FirstWord Pharma

Analyst Estimates: Here's What Brokers Think Of Shionogi & Co., Ltd. (TSE:4507) After Its Half-Ye...

Analyst Estimates: Here's What Brokers Think Of Shionogi & Co., Ltd. (TSE:4507) After Its Half-Year Report  simplywall.st

IDWeek 2025: Shionogi Presents Real-World and Surveillance Data Reinforcing Role of Cefiderocol A...

IDWeek 2025: Shionogi Presents Real-World and Surveillance Data Reinforcing Role of Cefiderocol Across Range of Patient Populations and Difficult-to-Treat Infections  Business Wire

Bioversys, Shionogi in CHF529M lung infection collaboration - BioWorld MedTech

Bioversys, Shionogi in CHF529M lung infection collaboration  BioWorld MedTech

Shionogi & Co. Reports Steady Q2 Earnings Amid Strategic Expansion - TipRanks

Shionogi & Co. Reports Steady Q2 Earnings Amid Strategic Expansion  TipRanks

Shionogi Eyes US Plant to Boost Antibiotic Production Amid Tariffs Challenge - JAPAN Forward

Shionogi Eyes US Plant to Boost Antibiotic Production Amid Tariffs Challenge  JAPAN Forward

Shionogi and UBE: Novel Antiviral Drug Demonstrates Efficacy in RSV Patients - 2 Minute Medicine

Shionogi and UBE: Novel Antiviral Drug Demonstrates Efficacy in RSV Patients  2 Minute Medicine

Shionogi & Co. Announces Merger with Shionogi Pharma to Strengthen Supply Chain - TipRanks

Shionogi & Co. Announces Merger with Shionogi Pharma to Strengthen Supply Chain  TipRanks

Shionogi Reports Mixed Q2 FY 2025 Results Amid Revenue Challenges - TipRanks

Shionogi Reports Mixed Q2 FY 2025 Results Amid Revenue Challenges  TipRanks

Shionogi’s Steady Earnings Came With A Dividend Sweetener - Finimize

Shionogi’s Steady Earnings Came With A Dividend Sweetener  Finimize

BioVersys joins forces with Shionogi on ansamycin development - The Pharma Letter

BioVersys joins forces with Shionogi on ansamycin development  The Pharma Letter

Shionogi pushes 2030 vision forward with $1 billion acquisition - The Pharma Letter

Shionogi pushes 2030 vision forward with $1 billion acquisition  The Pharma Letter

Shionogi to Acquire Japan Tobacco’s Pharmaceutical Business - TipRanks

Shionogi to Acquire Japan Tobacco’s Pharmaceutical Business  TipRanks

Japan's Shionogi plans US antibiotic plant with eye on Trump tariffs - Nikkei Asia

Japan's Shionogi plans US antibiotic plant with eye on Trump tariffs  Nikkei Asia

Shionogi inks new hearing loss research deal with Cilcare - The Pharma Letter

Shionogi inks new hearing loss research deal with Cilcare  The Pharma Letter

Gareth Morgan Named President of Qpex Biopharma, Inc. - Business Wire

Gareth Morgan Named President of Qpex Biopharma, Inc.  Business Wire

Shionogi puts up to $600m behind BioVersys antibiotics - pharmaphorum

Shionogi puts up to $600m behind BioVersys antibiotics  pharmaphorum

Shionogi to acquire Japan Tobacco pharma companies for $1.1B - BioWorld MedTech

Shionogi to acquire Japan Tobacco pharma companies for $1.1B  BioWorld MedTech

Shionogi Weighs Making Antibiotics in US Amid Rising Tariffs - Bloomberg.com

Shionogi Weighs Making Antibiotics in US Amid Rising Tariffs  Bloomberg.com

Roche, Shionogi Patents Deal Delays Alvogen’s Copies of Flu Drug - news.bloomberglaw.com

Roche, Shionogi Patents Deal Delays Alvogen’s Copies of Flu Drug  news.bloomberglaw.com

Shionogi Completes Acquisition of TORII PHARMACEUTICAL as Wholly-Owned Subsidiary - TipRanks

Shionogi Completes Acquisition of TORII PHARMACEUTICAL as Wholly-Owned Subsidiary  TipRanks

Ceolia takes over from Shionogi in marketing of Actair in Japan - The Pharma Letter

Ceolia takes over from Shionogi in marketing of Actair in Japan  The Pharma Letter

Eyes on Asia: Chugai, Mabwell, Shionogi - BioXconomy

Eyes on Asia: Chugai, Mabwell, Shionogi  BioXconomy

Shionogi's RSV antiviral reduces viral load in phase 2 trial of adults - Fierce Biotech

Shionogi's RSV antiviral reduces viral load in phase 2 trial of adults  Fierce Biotech

BARDA’s $375M to Shionogi for COVID-19 tops early list of 2025 grants - BioWorld MedTech

BARDA’s $375M to Shionogi for COVID-19 tops early list of 2025 grants  BioWorld MedTech

Drugmaker Shionogi to buy Japan Tobacco's unit Torii Pharmaceutical for $1 billion - Reuters

Drugmaker Shionogi to buy Japan Tobacco's unit Torii Pharmaceutical for $1 billion  Reuters

Shionogi & Co., Ltd. Announces Management Appointments - MarketScreener

Shionogi & Co., Ltd. Announces Management Appointments  MarketScreener

Transition of Promotional Activities for Allergen Immunotherapy Drug Actair® in Japan - Business ...

Transition of Promotional Activities for Allergen Immunotherapy Drug Actair® in Japan  Business Wire

Shionogi’s RSV antiviral reduces viral load in Phase II human challenge trial - Clinical Trials A...

Shionogi’s RSV antiviral reduces viral load in Phase II human challenge trial  Clinical Trials Arena

Shionogi Initiates First-Ever Human Study Testing Therapy for Ultra-Rare Jordan Syndrome - Neurol...

Shionogi Initiates First-Ever Human Study Testing Therapy for Ultra-Rare Jordan Syndrome  Neurology Live

Shionogi Completes Acquisition of TORII PHARMACEUTICAL as Wholly-Owned Subsidiary - The Globe and...

Shionogi Completes Acquisition of TORII PHARMACEUTICAL as Wholly-Owned Subsidiary  The Globe and Mail

Swiss firm BioVersys signs deal with Shionogi for antibiotics research - SWI swissinfo.ch

Swiss firm BioVersys signs deal with Shionogi for antibiotics research  SWI swissinfo.ch

The Leadership Connection - BOSS Publishing

The Leadership Connection  BOSS Publishing

Shionogi awarded $375m from HHS for preventative Covid-19 injectable - Pharmaceutical Technology

Shionogi awarded $375m from HHS for preventative Covid-19 injectable  Pharmaceutical Technology

Shionogi files in Japan to expand pediatric use of COVID-19 antiviral - The Pharma Letter

Shionogi files in Japan to expand pediatric use of COVID-19 antiviral  The Pharma Letter

Shionogi aims to buy tobacco giant's pharma unit for $1bn - pharmaphorum

Shionogi aims to buy tobacco giant's pharma unit for $1bn  pharmaphorum

Shionogi Investigational RSV Antiviral Reaches Primary Endpoint for Phase 2 Trial - Contagion Live

Shionogi Investigational RSV Antiviral Reaches Primary Endpoint for Phase 2 Trial  Contagion Live

Shionogi gets approval in Japan for ADHD digital therapeutic - pharmaphorum

Shionogi gets approval in Japan for ADHD digital therapeutic  pharmaphorum

Apnimed Provides Clinical Updates for Multiple Product Candidates - PR Newswire

Apnimed Provides Clinical Updates for Multiple Product Candidates  PR Newswire

Rating Change Observations: Shionogi & Co. upgraded, NRI downgraded, among others. - 富途牛牛

Rating Change Observations: Shionogi & Co. upgraded, NRI downgraded, among others.  富途牛牛

BioVersys inks deal worth CHF 479 M with Japan's Shionogi to treat infectious diseases - BioSpect...

BioVersys inks deal worth CHF 479 M with Japan's Shionogi to treat infectious diseases  BioSpectrum Asia

Shionogi Falls on Report of $1 Billion Offer to Buy Torii Pharma - Bloomberg.com

Shionogi Falls on Report of $1 Billion Offer to Buy Torii Pharma  Bloomberg.com

Apnimed Acquires Global Rights to Additional Sleep Apnea Drug Candidate - Sleep Review

Apnimed Acquires Global Rights to Additional Sleep Apnea Drug Candidate  Sleep Review

Shionogi Receives Award Through BARDA's Rapid Response Partnership Vehicle to Advance Long-Acting...

Shionogi Receives Award Through BARDA's Rapid Response Partnership Vehicle to Advance Long-Acting Formulation of S-892216, an Antiviral for COVID-19 Pre-Exposure Prophylaxis in At-Risk Populations  Business Wire

Shionogi & Co (4507 JP): Muted 1H Result; Solid HIV Business Leads FY Profit Guidance Raise - Sma...

Shionogi & Co (4507 JP): Muted 1H Result; Solid HIV Business Leads FY Profit Guidance Raise  Smartkarma

Japan's Shionogi-Torii Pharmaceutical merger conditionally cleared by JFTC - MLex

Japan's Shionogi-Torii Pharmaceutical merger conditionally cleared by JFTC  MLex

Japan's Shionogi inks new partnership agreement to support antimicrobial stewardship in Kenya - B...

Japan's Shionogi inks new partnership agreement to support antimicrobial stewardship in Kenya  BioSpectrum Asia

Shionogi and Jordan’s Guardian Angels Announce First-Ever Human Drug Study for Jordan’s Syndrome,...

Shionogi and Jordan’s Guardian Angels Announce First-Ever Human Drug Study for Jordan’s Syndrome, an Ultra-Rare Genetic Neurodevelopmental Disorder  BioSpace

Japanese drugmaker Shionogi to acquire JT's pharma units in $1.1bn deal - Nikkei Asia

Japanese drugmaker Shionogi to acquire JT's pharma units in $1.1bn deal  Nikkei Asia

Shionogi inks commercial deal for Cefiderocol in Australia and New Zealand - BioSpectrum Asia

Shionogi inks commercial deal for Cefiderocol in Australia and New Zealand  BioSpectrum Asia

His daughter has an ultra-rare genetic disorder. His push to treat it just hit a major milestone ...

His daughter has an ultra-rare genetic disorder. His push to treat it just hit a major milestone  CalMatters

BARDA to fund development of COVID preventive drug - CIDRAP

BARDA to fund development of COVID preventive drug  CIDRAP

China’s Ping An Insurance Wraps Up Exit From Joint Venture With Japanese Drug Giant Shionogi - Yi...

China’s Ping An Insurance Wraps Up Exit From Joint Venture With Japanese Drug Giant Shionogi  Yicai Global

Nxera and Shionogi launch Quviviq in Japan - The Pharma Letter

Nxera and Shionogi launch Quviviq in Japan  The Pharma Letter

Pharmalittle: We're reading about conflicts on U.S. vaccine panels, pharma DTC sales, and much mo...

Pharmalittle: We're reading about conflicts on U.S. vaccine panels, pharma DTC sales, and much more  statnews.com

Nxera Pharma and Shionogi Launch QUVIVIQ™ in Japan for Adults with Insomnia - Yahoo Finance

Nxera Pharma and Shionogi Launch QUVIVIQ™ in Japan for Adults with Insomnia  Yahoo Finance

A Pill to Prevent COVID-19 Shows Promise - Time Magazine

A Pill to Prevent COVID-19 Shows Promise  Time Magazine

Top Japanese firms steer USD1.1bn Japan pharma takeover - Law.asia

Top Japanese firms steer USD1.1bn Japan pharma takeover  Law.asia

Transition of Promotional Activities for Allergen Immunotherapy Drug Actair® in Japan - The AI Jo...

Transition of Promotional Activities for Allergen Immunotherapy Drug Actair® in Japan  The AI Journal

Notice of Head Office Relocation｜ 塩野義製薬 - Shionogi Inc.

Notice of Head Office Relocation｜ 塩野義製薬  Shionogi Inc.

Nxera Pharma and Shionogi Launch QUVIVIQ in Japan for Insomnia Treatment - Precedence Research

Nxera Pharma and Shionogi Launch QUVIVIQ in Japan for Insomnia Treatment  Precedence Research

hVIVO trial validates Shionogi's RSV candidate with 89% viral load reduction - Vox Markets

hVIVO trial validates Shionogi's RSV candidate with 89% viral load reduction  Vox Markets

Merging with the US biotech venture Qpex: A chronicle of striving for the integration process aim...

Merging with the US biotech venture Qpex: A chronicle of striving for the integration process aimed at maximizing value  Shionogi Inc.

SHIONOGI’s Commitment to Antibiotics: Aiming for an Ideal Collaboration between Industry, Governm...

SHIONOGI’s Commitment to Antibiotics: Aiming for an Ideal Collaboration between Industry, Government, and Academia to Tackle Infectious Diseases  Shionogi Inc.

Message from Top Management - Shionogi Inc.

Message from Top Management  Shionogi Inc.

Shionogi presents pivotal ensitrelvir fumaric acid Phase 3 data and exploratory long COVID data -...

Shionogi presents pivotal ensitrelvir fumaric acid Phase 3 data and exploratory long COVID data  European AIDS Treatment Group

Masahiro Fujita - Shionogi Inc.

Masahiro Fujita  Shionogi Inc.

What we stand for: Takeki Uehara | Clinical Development Vision and Strategy | Shionogi & Co., Ltd...

What we stand for: Takeki Uehara | Clinical Development Vision and Strategy | Shionogi & Co., Ltd.  Shionogi Inc.

Nathan McCutcheon - Shionogi Inc.

Nathan McCutcheon  Shionogi Inc.

NIH trial to evaluate Shionogi antiviral in adults hospitalized with COVID-19 - National Institut...

NIH trial to evaluate Shionogi antiviral in adults hospitalized with COVID-19  National Institutes of Health (.gov)

Improving affordability for patients in need - Shionogi Inc.

Improving affordability for patients in need  Shionogi Inc.

Pharma sector sees $6.96 billion in global deal activity in May 2025, led by GSK, Shionogi, and E...

Pharma sector sees $6.96 billion in global deal activity in May 2025, led by GSK, Shionogi, and Eli Lilly: GlobalData  Express Pharma

Shionogi’s Harmonized Data Foundation Powers Multiple Successful Launches - Veeva

Shionogi’s Harmonized Data Foundation Powers Multiple Successful Launches  Veeva

Annual Report / Integrated Report / Environment Report - Shionogi Inc.

Annual Report / Integrated Report / Environment Report  Shionogi Inc.

Financial Highlights - Shionogi Inc.

Financial Highlights  Shionogi Inc.

Shionogi to acquire Qpex Biopharma for $140m - Pharmaceutical Technology

Shionogi to acquire Qpex Biopharma for $140m  Pharmaceutical Technology

Japan to grant emergency approval to Shinogi COVID-19 drug - Reuters

Japan to grant emergency approval to Shinogi COVID-19 drug  Reuters

Shionogi secures license for Maze’s Pompe disease treatment - Pharmaceutical Technology

Shionogi secures license for Maze’s Pompe disease treatment  Pharmaceutical Technology

Notice Regarding the Launch of the new SHIONOGI Group Brand - Shionogi Inc.

Notice Regarding the Launch of the new SHIONOGI Group Brand  Shionogi Inc.

ViiV Healthcare announces exclusive license agreement with Shionogi to develop third-generation H...

ViiV Healthcare announces exclusive license agreement with Shionogi to develop third-generation HIV integrase inhibitor with potential for ultra long-acting dosing intervals  GSK

Investigator-Initiated Research - Shionogi Inc.

Investigator-Initiated Research  Shionogi Inc.

Japan's Shionogi says COVID-19 pill shows rapid clearance of virus - Reuters

Japan's Shionogi says COVID-19 pill shows rapid clearance of virus  Reuters